RP105-Negative B Cells in Systemic Lupus Erythematosus

Abstract EN

Systemic lupus erythematosus (SLE) is a multisystem disease characterized by B cells producing autoantibodies against nuclear proteins and DNA, especially anti-double-strand DNA (dsDNA) antibodies.

RP105 (CD180), the toll-like receptor- (TLR-) associated molecule, is expressed on normal B cells.

However, RP105-negative B cells increase in peripheral blood from patients with active SLE.

RP105 may regulate B-cell activation, and RP105-negative B cells produce autoantibodies and take part in pathophysiology of SLE.

It is possible that targeting RP105-negative B cells is one of the treatments of SLE.

In this paper, we discuss the RP105 biology and clinical significance in SLE.